Fundraising Fox
🦊/Companies
Sign in

Coave Therapeutics

Paris, FR · 8 known investors

Find your way into Coave Therapeutics

Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision. The company focuses on treating retinal vascular diseases and other genetic conditions where traditional gene therapy delivery has been limited.

BiotechDeep TechHealthtechMedical Devices

Investors · 8

Fund+Leuven · $5.5M – $16.5M
Kurma PartnersParis · $162K – $10.8M
Seroba Life SciencesDublin · $540K – $7.6M
V-Bio VenturesGhent · $270K – $2.2M
BpifrancereportedParis, Ile-De-France · $270K
InvusreportedNew York
Novo HoldingsreportedCopenhagen · $1.1M – $54M
UI InvestissementreportedParis

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries AJan 2025
    Source ↗
  • Undisclosed amountSeries BJul 2021 · 2 sources
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Coave Therapeutics went on to found or lead other companies.

Aravind AsokanScientific Advisory BoardFounded StridebioHervé SchaffhauserDirector Translational NeuroscienceFounded Amporin

In the news

Coave Therapeutics Launches CNS-Targeted Gene Therapy Capsid Developed with Proprietary Platform | BioPharm Internationalbiopharminternational.com · May 2026Coave raises $33m funding to advance ALIGATER platformpharmaceutical-technology.com · Jan 2025Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicinesglobenewswire.com · Jan 2025Coave Therapeutics Closes €33M in Series B Financing - FinSMEsfinsmes.com · Jul 2021Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platformprnewswire.com · Jul 2021

Frequently asked questions

What does Coave Therapeutics do?
Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision. The company focuses on treating retinal vascular diseases and other genetic conditions where traditional gene therapy delivery has been limited.
Who are Coave Therapeutics's investors?
Coave Therapeutics's investors include Fund+, Kurma Partners, Seroba Life Sciences, V-Bio Ventures, Bpifrance, Invus, Novo Holdings, UI Investissement.
Where is Coave Therapeutics headquartered?
Coave Therapeutics is headquartered in Paris, FR.